NeoGenomics, Inc. (NASDAQ:NEO) Director Bruce K. Crowther sold 20,734 shares of the stock in a transaction dated Tuesday, June 8th. The stock was sold at an average price of $41.46, for a total transaction of $859,631.64. Following the transaction, the director now directly owns 59,564 shares of the company’s stock, valued at $2,469,523.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of NEO stock traded up $0.27 during trading hours on Thursday, hitting $42.87. The company’s stock had a trading volume of 388,479 shares, compared to its average volume of 918,972. The stock has a fifty day moving average of $44.28. The firm has a market capitalization of $5.06 billion, a PE ratio of -531.63 and a beta of 0.69. NeoGenomics, Inc. has a twelve month low of $25.67 and a twelve month high of $61.57. The company has a current ratio of 13.91, a quick ratio of 13.60 and a debt-to-equity ratio of 0.63.
NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Wednesday, May 5th. The medical research company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.05). The business had revenue of $115.30 million during the quarter, compared to analyst estimates of $112.17 million. NeoGenomics had a negative net margin of 2.42% and a positive return on equity of 0.83%. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.07) earnings per share. On average, analysts anticipate that NeoGenomics, Inc. will post -0.33 earnings per share for the current fiscal year.
Several research analysts recently issued reports on NEO shares. Zacks Investment Research cut shares of NeoGenomics from a “hold” rating to a “sell” rating in a report on Wednesday, April 28th. Needham & Company LLC restated a “buy” rating and set a $65.00 target price on shares of NeoGenomics in a research report on Friday, April 16th. Morgan Stanley upped their target price on shares of NeoGenomics from $46.00 to $64.00 and gave the stock an “overweight” rating in a research report on Thursday, February 25th. The Goldman Sachs Group initiated coverage on shares of NeoGenomics in a research report on Thursday, June 3rd. They set a “buy” rating and a $55.00 target price on the stock. Finally, Raymond James restated a “market perform” rating on shares of NeoGenomics in a research report on Wednesday, March 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company’s stock. NeoGenomics currently has an average rating of “Buy” and an average price target of $50.46.
NeoGenomics Company Profile
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains.
Read More: Cash Flow Analysis in Stock Selection
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.